{"filings":[{"id":1571516,"accession_number":"0001477932-26-004244","cik":1096938,"company_name":"United Health Products, Inc.","ticker":"UEEC","form_type":"8-K","filed_at":"2026-07-10T16:19:24+00:00","items":["8.01","9.01"],"status":"ready","headline":"United Health Products partners with NAMSA to sponsor clinical study of CelluSTAT for FDA PMA","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["NAMSA will serve as regulatory sponsor, seeking an IDE to conduct a clinical study of CelluSTAT Hemostatic Gauze.","UHP will hold exclusive right of reference to all study data for use in a revised PMA application.","The study is part of efforts to resolve the outstanding FDA Warning Letter.","NAMSA has decades of experience in clinical trial management for Class III hemostatic agents and FDA CDRH.","CEO Brian Thom expressed confidence in NAMSA's ability to gain IDE approval and efficiently sponsor the study."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":14321207.516040329,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117617,"accession_number":"0001477932-25-009157","cik":1096938,"company_name":"United Health Products, Inc.","ticker":"UEEC","form_type":"8-K","filed_at":"2025-12-22T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"United Health Products secures $289,821 convertible note from Alumni Capital at 15% and $4M AMPA","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Net proceeds of $250,000 from $289,821 senior convertible note; 15% annual interest; maturity Dec 31, 2026.","Note convertible at $0.06 per share; Alumni limited to <9.99% of outstanding common stock.","AMPA allows company to sell up to $4M of common stock at 90% of VWAP; term through Dec 31, 2027.","Alumni receives 5-year warrant to purchase 3,484,321 shares at $0.075 per share.","Company must file resale registration statement (Form S-1) by Jan 15, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":14321207.516040329,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150802,"accession_number":"0001477932-25-004608","cik":1096938,"company_name":"United Health Products, Inc.","ticker":"UEEC","form_type":"8-K","filed_at":"2025-06-16T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"United Health Products CFO Kristofer Heaton resigns; CEO Brian Thom assumes interim PFO role","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Kristofer Heaton resigned as VP of Finance and Principal Financial Officer effective June 12, 2025, citing personal and professional factors.","CEO Brian Thom will serve as interim principal financial officer while the company seeks a permanent replacement.","No further details on Heaton's departure or transition plan were provided."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":14321207.516040329,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150801,"accession_number":"0001477932-25-003453","cik":1096938,"company_name":"United Health Products, Inc.","ticker":"UEEC","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"United Health Products uplisted to OTCQB; FDA declines IDE for CelluSTAT study","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Common stock upgraded from OTC Pink to OTCQB effective May 1, 2025; ticker UEEC.","FDA declined to approve IDE for follow-on CelluSTAT clinical study, citing BIMO audit findings from initial 2019 study.","Company responded to audit findings in Oct 2024 and Apr 2025; teleconference with FDA scheduled within 10 days.","No assurance that FDA Premarket Approval for CelluSTAT will be granted."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":14321207.516040329,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186786,"accession_number":"0001477932-24-006902","cik":1096938,"company_name":"United Health Products, Inc.","ticker":"UEEC","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"UHP FDA PMA update: supplemental study needed for organ space, 6-7 month delay","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA requires additional clinical data for CelluSTAT (HemoStyp) use in intestinal/thoracic procedures.","Pivotal study (232 patients, 118 treated) showed non-inferiority and superiority for time to hemostasis.","Company will enroll limited number of human subjects in multi-site supplemental study, taking ~6-7 months.","FDA review period remains paused until all deficiencies addressed; ~90 of 180 days elapsed.","Additional biocompatibility and sterility testing agreed with FDA; BIMO site inspections completed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":14321207.516040329,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219700,"accession_number":"0001477932-24-003854","cik":1096938,"company_name":"United Health Products, Inc.","ticker":"UEEC","form_type":"8-K","filed_at":"2024-06-25T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"United Health Products amends equity line pricing terms with White Lion Capital","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment No. 2 to Common Stock Purchase Agreement (CSPA) dated June 20, 2024.","Purchase price changed to 93% of daily VWAP (95% if on national exchange) with $0.25 floor.","If floor waived, price equals 90% of lower of three lowest VWAPs or closing price.","All other terms of original September 2022 CSPA remain unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":14321207.516040329,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":312368,"accession_number":"0001477932-23-000656","cik":1096938,"company_name":"United Health Products, Inc.","ticker":"UEEC","form_type":"8-K","filed_at":"2023-01-31T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"United Health Products updates FDA PMA progress for HemoStyp Gauze; amends White Lion agreement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["FDA update: batch lot from new mfg shown identical to human trial product; additional lots undergoing consistency testing.","Company believes consistent production is key criterion for PMA; final application will include test results.","No assurance that PMA application will be approved by FDA.","Amended CSPA with White Lion: purchase price set at 90% of VWAP if stock below $0.25 and floor waived (previously 93%).","Company has raised over $350,000 under the CSPA since September 2022; all other terms unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":14321207.516040329,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":348465,"accession_number":"0001477932-22-006710","cik":1096938,"company_name":"United Health Products, Inc.","ticker":"UEEC","form_type":"8-K","filed_at":"2022-09-07T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"United Health Products enters $10M equity line with White Lion; receives $200k and 2M shares from former exec settlement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered common stock purchase agreement with White Lion Capital for up to $10M over 36 months.","Issued 757,576 commitment shares; purchase price at 93% of VWAP or closing floor of $0.30.","Received ~$200k cash and 2M shares returned from former executive; shares available for reissuance.","Litigation settlement with auditor-related defendant will yield cash payment this month.","FDA PMA process continues; audit and production completion expected within 60 days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":14321207.516040329,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":348464,"accession_number":"0001477932-22-005227","cik":1096938,"company_name":"United Health Products, Inc.","ticker":"UEEC","form_type":"8-K","filed_at":"2022-07-19T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"UHP meets with FDA on PMA; manufacturing validation needed for review completion","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["On July 13, 2022, UHP and its consultant met with FDA team to discuss observations from initial PMA review.","FDA indicated validation of certain manufacturing process elements is needed to complete PMA review.","UHP to work expeditiously with manufacturing partner in coming weeks to accomplish remaining tasks.","No assurance that PMA application will be approved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":14321207.516040329,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":365160,"accession_number":"0001477932-22-004603","cik":1096938,"company_name":"United Health Products, Inc.","ticker":"UEEC","form_type":"8-K","filed_at":"2022-06-23T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"United Health Products settles SEC investigation; former CEO to disgorge $1.02M to company","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["SEC settlement requires permanent injunctions and $450,000 civil penalty payable over 270 days.","Former CEO Douglas Beplate to pay $1,020,000 disgorgement to UHP over next six months.","CEO Brian Thom's RSU grant increased 15% to 13.225M shares; vesting upon FDA premarket approval jumps from 5% to 20%.","Independent Director Robert Denser granted 1M RSUs vesting upon $30M cumulative revenue or change of control."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":14321207.516040329,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":365159,"accession_number":"0001477932-22-004276","cik":1096938,"company_name":"United Health Products, Inc.","ticker":"UEEC","form_type":"8-K","filed_at":"2022-06-10T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"United Health Products settles SEC probe; FDA PMA meeting moved to July 13","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Accepted SEC settlement terms; complaint filed June 8, 2022; consent judgment to follow; no terms for individuals Beplate, Schiliro.","FDA Class III PMA meeting rescheduled to July 13 from July 6 at FDA's request.","Settlement terms previously reported in 2021 Annual Report and April 29, 2022 8-K.","No additional FDA requests for information received as of this date on PMA application."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":14321207.516040329,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":365158,"accession_number":"0001477932-22-002742","cik":1096938,"company_name":"United Health Products, Inc.","ticker":"UEEC","form_type":"8-K","filed_at":"2022-04-29T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"United Health Products receives proposed SEC settlement terms including $450K penalty","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["SEC proposed settlement requires $450,000 civil penalty and permanent injunction against company.","Company would not admit or deny allegations, with restrictions on public statements.","Penalty payable in four installments over 270 days with statutory interest.","Company is predisposed to accept, pending clarification on injunctive relief and complaint draft.","Proposed settlement does not cover former CEO Douglas Beplate or former COO Louis Schiliro."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":14321207.516040329,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":384757,"accession_number":"0001477932-22-001045","cik":1096938,"company_name":"United Health Products, Inc.","ticker":"UEEC","form_type":"8-K","filed_at":"2022-02-24T23:59:59+00:00","items":["5.02","8.01"],"status":"ready","headline":"Two directors resign amid SEC investigation; COO steps down but remains in non-officer role","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Douglas Beplate resigns as director and chairman; Louis Schiliro resigns as director and COO, effective Feb 28, 2022.","Resignations tied to ongoing SEC investigation into 2017 revenue recognition; SEC may seek remedies against both individuals.","SEC private investigation since Nov 2018; company restated 2017-2018 financials in July 2020.","Company in dialogue with SEC staff for resolution; unable to predict outcome or enforcement actions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":14321207.516040329,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":402638,"accession_number":"0001477932-21-009117","cik":1096938,"company_name":"United Health Products, Inc.","ticker":"UEEC","form_type":"8-K","filed_at":"2021-12-10T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"CEO Brian Thom sells shares for tax purposes; holdings rise to 1,368,657 shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Brian Thom completed open-market sales of common stock to satisfy tax obligations and personal expenses.","Mr. Thom has received no cash compensation since December 2020; restricted shares used for accrued compensation.","Holdings increased by 326,746 shares to 1,368,657 shares from 1,041,911 at Jan 1, 2021.","Disclosure made under Item 7.01 Regulation FD; no material business impact cited."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":14321207.516040329,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":402637,"accession_number":"0001477932-21-007247","cik":1096938,"company_name":"United Health Products, Inc.","ticker":"UEEC","form_type":"8-K","filed_at":"2021-10-14T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"United Health Products updates on FDA PMA process and Triton Funds investment","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["FDA requested details on HemoStyp manufacturing process; UHP implemented GMP software tool and will respond later this month.","SEC declared UHP's registration statement effective on September 29, allowing closure of $4M-$6M stock purchase with Triton Funds.","UHP produced a prototype of new HemoStyp format for trauma/surgical applications; further testing planned.","Company will host investor information session on October 15, 2021 at 9am ET."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":14321207.516040329,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}